NEW CLASSES OF ANION RECEPTOR-CONTAINING CHARGED AND NEUTRAL TRANSITION-METAL LEWIS ACIDIC RECOGNITION SITES by Beer, P, Dickson, C, Fletcher, N, Goulden, A, Grieve, A, Hodacova, J, Wear, T

Cyclin D1 is not an essential target of beta-catenin signaling during intestinal tumorigenesis, but it may act as a modifier of disease severity in multiple intestinal neoplasia (M... by Wilding, J, Straub, J, Bee, J, Churchman, M, Bodmer, W, Dickson, C, Tomlinson, I, Ilyas, M

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo by Taylor, P, Fleischmann, R, Perkins, E, Lisse, J, Zhu, B, Gaich, C, Zhang, X, Schlichting, D, Dickson, C, Takeuchi, T

Imaging plasma membrane phase behaviour in live cells using a thiophene-based molecular rotor. by Dent, M, López-Duarte, I, Dickson, C, Chairatana, P, Anderson, H, Gould, I, Wylie, D, Vyšniauskas, A, Brooks, N, Kuimova, M

IP6 is an HIV pocket factor that prevents capsid collapse and promotes DNA synthesis by Mallery, D, Márquez, C, McEwan, W, Dickson, C, Jacques, D, Anandapadamanaban, M, Bichel, K, Towers, G, Saiardi, A, Böcking, T, James, L

The Gemini-North multiobject spectrograph stability performance by Murowinski, R, Allington-Smith, JR, Beard, S, Crampton, D, Davies, R, Dickson, C, Hook, I, Jørgensen, I, Juneau, S, Marshall, G, Szeto, K, Tierney, C

Baricitinib 4mg and 2mg once-daily reduced pain in both patients who were opioid users and non-users in active rheumatoid arthritis: a post-hoc analysis of phase 3 trials by Pope, J, Lee, Y, Curtis, J, Mo, D, Rooney, T, Xie, L, Dickson, C, Schlichting, D, Quebe, A, Cardoso, A, Simon, L, Taylor, P

Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors by Taylor, P, Fleischmann, R, Takeuchi, T, Pope, J, Genovese, M, Zhu, B, Gaich, C, Zhang, X, Dickson, C, Quebe, A, De Leonardis, F, Cardoso, A, Kouris, I, Durez, P

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial by Taylor, P, Lee, Y, Fleischmann, R, Takeuchi, T, Perkins, E, Fautrel, B, Zhu, B, Quebe, A, Gaich, C, Zhang, X, Dickson, C, Schlichting, D, Patel, H, Durand, F, Emery, P

The Gemini-North multiobject spectrograph integration, test and commissioning by Hook, I, Allington-Smith, JR, Beard, S, Crampton, D, Davies, R, Dickson, C, Ebbers, A, Fletcher, M, Jørgensen, I, Jean, I, Juneau, S, Murowinski, R, Nolan, R, Laidlaw, K, Leckie, B, Marshall, G, Purkins, T, Richardson, I, Roberts, S, Simons, D, Smith, M, Stilburn, J, Szeto, K, Tierney, C, Wolff, R

The GEMINI multiobject spectrographs by Murowinski, R, Bond, T, Crampton, D, Davidge, T, Fletcher, J, Leckie, B, Morbey, C, Roberts, S, Saddlemyer, L, Sebesta, J, Stilburn, J, Szeto, K, Allington-Smith, JR, Content, R, Davies, R, Dodsworth, G, Haynes, R, Robinson, D, Robertson, D, Webster, J, Lee, D, Beard, S, Dickson, C, Kelly, D, Bennet, R

The Gemini-North Multiobject Spectrograph integration, test and commissioning by Hook, I, Allington-Smith, JR, Beard, S, Crampton, D, Davies, R, Dickson, C, Ebbers, A, Fletcher, M, Jorgensen, I, Jean, I, Juneau, S, Murowinski, R, Nolan, R, Laidlaw, K, Leckie, B, Marshall, G, Purkins, T, Richardson, I, Roberts, S, Simons, D, Smith, M, Stilburn, J, Szeto, K, Tierney, C, Wolff, R